Presage Biosciences in-licenses trial stage drug program

Privately-held Presage Biosciences said it has in-licensed voruciclib, its first clinical stage drug program.

Voruciclib is an oral CDK inhibitor that has been in clinical development for cancer indications and will be developed in combination with other standard of care agents.

Nathan Caffo, president of Presage, said: “Using our CIVO platform, we have been able to rapidly identify and understand the biology of voruciclib combinations that hold potential for further clinical development. CIVO clearly distinguished voruciclib from other CDK inhibitors in ways that were unexpected.”